GlaxoSmithKline is a leading research-based pharmaceutical company, and is the culmination of the merger of two of the industry’s premier companies with years of pioneer studies and breakthroughs.
Its expertise has seen the company become the leading manufacturer of products in the four major therapeutic areas of anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal / metabolic medication. It is also making vast headway in the increasingly important area of vaccines.
GSK Pharmaceuticals in Malaysia has 7% market share of ethical pharmaceuticals, and is a market leader in 4 key therapeutic areas: respiratory, metabolic, anti-infectives and vaccines.
Strong collaboration exists with physicians working in established government hospitals nationwide. This contributes to local Good Clinical Practice (GCP) standard as well as helps develop biomedical research for Malaysia.
Asia is experiencing some of the fastest rates of growth in the standards of living and with this comes the demand for quality healthcare at a reasonable cost. GSK is committed to providing this and ensuring that people have the opportunity to lead healthier, better and longer lives.